What Are the Crystals That Cause Gout and Pseudogout?

The Crystalline Culprits: Understanding Gout and Pseudogout

By Rony Kampalath, MD
Medically reviewed by David Ozeri, MD
Last updated: October 21, 2023

Crystal-induced arthropathies represent a distinct category of joint diseases where microscopic crystals precipitate within joint spaces. This abnormal accumulation triggers a powerful inflammatory response, leading to considerable pain, swelling, and, if left unchecked, significant joint damage over time. Among these conditions, gout is perhaps the most widely recognized, characterized by the deposition of monosodium urate, or uric acid, crystals. A closely related, yet distinct, condition known as pseudogout, or calcium pyrophosphate deposition (CPPD) disease, results from the formation of calcium pyrophosphate dihydrate crystals. Understanding these crystalline invaders is key to effective management and improved quality of life.

Gout is a remarkably prevalent condition, affecting over 3% of adults in the United States, underscoring its significant public health impact. Similarly, pseudogout is quite common, particularly as individuals age, with approximately 3% of people in their sixties experiencing the condition, and this figure rising dramatically to nearly half of those in their nineties. While the underlying crystalline compositions of these two arthropathies differ, their clinical manifestations often overlap, leading to the descriptive term "pseudogout" to highlight this resemblance. This can sometimes make differentiation challenging without specific diagnostic tests.

Despite their varying origins and crystalline structures, both gout and pseudogout present across a broad spectrum of severity. Some individuals may experience asymptomatic crystal deposition, never developing symptoms, while others endure severe, debilitating illness marked by intense pain and functional limitations. Regardless of the presentation, it is crucial to recognize that both conditions are treatable. However, successful management necessitates a highly individualized approach, taking into account each patient's unique symptoms, overall health status, and response to therapy. Tailored strategies are essential for controlling inflammation and preventing long-term complications.

powerofforever / Getty Images

Types of Crystals

Monosodium Urate Crystals

Monosodium urate crystals are derived from uric acid, a naturally occurring compound in the blood. Uric acid is the end product of purine metabolism, with purines being substances found in human cells and in many foods. Typically, the body maintains a delicate balance, with excess uric acid efficiently eliminated via the kidneys and the gut. However, disruptions in this excretory process, often due to reduced kidney efficiency, can lead to a buildup of uric acid in the bloodstream. Less frequently, certain metabolic disorders can cause the body to produce an excessive amount of uric acid, also contributing to elevated levels.

Dietary choices and alcohol consumption can notably influence serum uric acid concentrations. Foods rich in purines, such as red meat and seafood, are known to increase uric acid levels, and their overconsumption has historically been linked to gout flares. Certain alcoholic beverages, particularly beer, also significantly contribute to this elevation. While lifestyle factors undoubtedly play a role, it's important to understand that a significant genetic predisposition often dictates an individual's baseline uric acid levels, explaining why some people are more susceptible to gout than others, even with similar diets.

Calcium Pyrophosphate Dihydrate (CPPD) Crystals

Calcium pyrophosphate dihydrate (CPPD) crystals, responsible for pseudogout, originate within the joint cartilage itself. Cartilage cells, known as chondrocytes, naturally produce a substance called pyrophosphate. For reasons that are not yet fully elucidated by medical science, there can be an abnormal increase in pyrophosphate levels within the cartilage. This elevated concentration, coupled with other factors, can lead to the spontaneous formation and subsequent deposition of CPPD crystals within the joint structures. These crystals then trigger an inflammatory response, mirroring that seen in gout.

An intriguing aspect of these crystal-induced arthropathies is the potential for overlap. It has been observed that the two types of crystals are not mutually exclusive; approximately 5% of patients diagnosed with gout also present with CPPD crystals within their joints. This co-occurrence can complicate diagnosis and treatment, as symptoms from both conditions might manifest simultaneously or sequentially. Therefore, a comprehensive diagnostic approach is vital to identify all contributing factors and ensure the most effective and targeted management plan for the individual.

Causes

Monosodium Urate Crystals

For monosodium urate crystals to form and trigger gout, persistently elevated levels of uric acid in the blood, a condition known as hyperuricemia, are a prerequisite. Uric acid is primarily synthesized in the liver through the metabolic processing of purines, which can either be produced by the body itself (endogenous) or ingested from various foods (exogenous). While most uric acid is efficiently removed from the body through renal excretion in urine and via the gastrointestinal tract, any disruption to this delicate balance can lead to its accumulation and crystallization within joints.

The majority of cases of hyperuricemia stem from a diminished efficiency of uric acid excretion by the kidneys. This renal inefficiency can be attributed to several common medical conditions and lifestyle factors. These include widespread issues such as obesity, which alters metabolic pathways; chronic kidney disease, directly impairing excretory function; dehydration, concentrating bodily fluids; and hypothyroidism, affecting overall metabolic rate. Less frequently, specific inherited genetic disorders can also predispose individuals to hyperuricemia, either by impeding uric acid excretion or by accelerating its production, highlighting the diverse etiologies.

Historically, gout earned the moniker "disease of kings" due to its association with affluent lifestyles, particularly involving overconsumption of rich foods and alcohol. While diet and lifestyle habits undeniably influence serum uric acid levels—foods high in purines, like organ meats and certain seafood, and excessive alcohol intake are known contributors—current research suggests that genetic predispositions often exert a more profound impact on an individual's susceptibility to hyperuricemia and, consequently, gout. Understanding this interplay between genetics and lifestyle is crucial for both prevention and treatment strategies.

Calcium Pyrophosphate Dihydrate Crystals

The precise mechanisms leading to the formation and deposition of calcium pyrophosphate dihydrate (CPPD) crystals in the joints remain less thoroughly understood compared to gout. However, several contributing factors have been identified. In some instances, the predisposition to CPPD crystal formation appears to be inherited, a condition termed familial chondrocalcinosis, suggesting a genetic component. Furthermore, significant joint trauma, whether from injuries or surgical procedures, can sometimes act as a catalyst for crystal deposition, indicating mechanical stress may play a role in initiating the process.

Beyond inherited predispositions and physical trauma, CPPD disease is also associated with certain systemic metabolic conditions. For example, hemochromatosis, a disorder characterized by excessive iron accumulation in the body, and hyperparathyroidism, which leads to abnormally high levels of parathyroid hormone and calcium in the blood, have both been linked to an increased risk of pseudogout. Additionally, some rare genetic disorders further contribute to the development of this condition, emphasizing the complex interplay of genetic, metabolic, and environmental factors in CPPD crystal formation and subsequent joint inflammation.

Symptoms and Complications

Gout

Gout exhibits a wide spectrum of clinical manifestations, affecting not only various joints but also the kidneys. Broadly, the condition can lead to either acute, intensely painful episodes of joint inflammation or evolve into a chronic state of persistent joint damage. Characteristic complications include the accumulation of urate crystals in soft tissues, forming deposits known as tophi, the development of painful kidney stones, and potentially chronic kidney disease due to long-term hyperuricemia. Patients may also experience more generalized symptoms such as fever or a feeling of malaise during acute attacks.

An acute gout flare-up typically involves a single joint, though it can occasionally affect multiple joints simultaneously. These attacks are characterized by sudden onset of excruciating pain, often described as throbbing or crushing, accompanied by marked redness, warmth, and swelling of the affected joint. While gout can target any joint, it shows a particular predilection for the first metatarsophalangeal joint at the base of the big toe, an area famously affected, or the knee. The severity of the pain often prevents even the lightest touch, such as a bedsheet.

Numerous factors can precipitate an acute gout flare, acting as triggers that disturb the delicate balance of uric acid. These include physical trauma to a joint, recent surgery, periods of starvation or rapid weight loss, and dehydration. Certain foods, particularly those high in purines like organ meats and specific seafood, and excessive alcohol intake are also common culprits. Additionally, some medications can induce an attack. While these flares typically resolve spontaneously within days to a few weeks, without appropriate management, attacks tend to become more frequent, last longer, and eventually may not fully remit, leading to chronic, destructive joint disease.

Tophaceous gout represents a more advanced stage of the disease, characterized by the formation of solid, chalky collections of uric acid crystals within soft tissues. These deposits, known as tophi, occur when chronically elevated uric acid levels lead to significant crystal accumulation, causing localized inflammation and tissue damage. Tophi are commonly found around joints, within tendons, and in bursae (fluid-filled sacs that cushion joints), but can also appear in less typical locations like the ears or other soft tissues. While often visible and palpable as firm nodules, they are surprisingly often not painful or tender to the touch themselves, though they indicate ongoing systemic disease.

Beyond direct joint involvement, chronically elevated levels of uric acid can significantly impact kidney health. The two primary renal complications associated with gout are uric acid kidney stones and chronic renal disease, also known as chronic urate nephropathy. Kidney stones form when uric acid crystallizes in the urine, leading to excruciating flank pain and sometimes blood in the urine. Chronic urate nephropathy, on the other hand, involves long-term damage to kidney function due to persistent hyperuricemia, potentially progressing to impaired kidney function and requiring ongoing medical management to preserve renal health.

Pseudogout

Calcium pyrophosphate deposition disease (CPPD) also presents with a wide range of manifestations, from being entirely asymptomatic, where crystals are present but cause no symptoms, to causing acute or chronic debilitating joint disease. Unlike gout, which often targets smaller joints, CPPD disease more commonly affects larger joints. Its unpredictable nature means symptoms can vary significantly between individuals and even within the same person over time, necessitating a careful diagnostic approach to accurately distinguish it from other arthritic conditions and provide appropriate treatment.

Acute CPPD disease attacks typically involve one or several joints, similar to gout flares, but often in larger joints. These acute episodes can be triggered by events such as joint injury, recent surgery, or periods of severe illness, suggesting that physical stress or systemic inflammation can provoke crystal release and subsequent inflammatory reactions. The knee is a particularly common site for acute CPPD attacks, but other major joints like the wrists, shoulders, ankles, feet, and elbows can also be affected. The variability in affected joints underscores the widespread nature of crystal deposition.

Patients experiencing an acute CPPD attack commonly report symptoms of pain, swelling, redness, and warmth in the affected joint, alongside a significant decrease in its functional capacity. These symptoms closely resemble those of an acute gout flare, which often leads to initial misdiagnosis. While the illness typically resolves spontaneously within a period ranging from a few days to several weeks, the intensity of symptoms can be substantial, warranting medical intervention for pain relief and inflammation management. The self-limiting nature does not diminish the need for diagnosis and supportive care.

Chronic CPPD disease can present with symptoms that mimic other well-known forms of arthritis, complicating accurate diagnosis. In some cases, its symptoms may closely parallel those of degenerative osteoarthritis, characterized by progressive joint degeneration, stiffness, and pain, especially during activity. This overlap often makes it challenging to differentiate whether observed joint changes are due to CPPD or primary osteoarthritis, or a combination of both. Furthermore, chronic CPPD can contribute to or exacerbate existing osteoarthritic changes, creating a complex clinical picture for patients and clinicians alike.

Another significant clinical mimicry is chronic CPPD disease imitating rheumatoid arthritis (RA). Patients might experience symptoms typically associated with RA, including prolonged morning stiffness, generalized fatigue, and restricted range of motion in affected joints. This form of CPPD disease may involve multiple joints in both the arms and legs, with inflammation that can wax and wane over several months, further blurring the lines with RA. Individuals with higher risk factors for pseudogout include those with hemochromatosis (excess iron storage), low magnesium levels, an overactive parathyroid gland (hyperparathyroidism), or persistently high blood calcium, all of which can predispose to crystal formation.4

Diagnosis

Gout

When an acute gout attack is suspected, a physician employs a multi-faceted approach to confirm the diagnosis. This typically involves a thorough review of the patient's medical history, a comprehensive physical examination of the affected joints, and an evaluation of laboratory findings, often including a blood test to measure uric acid levels. While elevated uric acid strongly supports the suspicion, the definitive diagnosis of gout, especially during a first episode of arthritis, is established through the direct identification of monosodium urate crystals within the affected joint fluid. This provides undeniable proof of the condition.

The crucial step in identifying uric acid crystals involves a procedure known as arthrocentesis, a relatively simple process where a small amount of fluid is drawn directly from the inflamed joint. This synovial fluid is then meticulously examined under a polarized light microscope. Under this specialized illumination, gout crystals present a distinctive appearance: they are needle-shaped and display a characteristic yellow color when aligned parallel to the compensator, a property scientifically termed "negative birefringence." This unique optical property is key to differentiating gout from other crystal-induced arthropathies.

While synovial fluid analysis for crystal identification is the gold standard, there are instances where obtaining joint fluid might not be feasible or where crystal presence cannot be definitively established. In such cases, your healthcare provider may still be able to make a presumptive diagnosis of gout based on a strong clinical suspicion, supported by your detailed history of symptoms, characteristic physical exam findings, and typical X-ray changes. Imaging studies, while not diagnostic of crystals directly, can reveal joint damage or tophi consistent with chronic gout, aiding in the overall assessment.

Patients with uric acid kidney stones, a common complication of gout, may present with distinct symptoms such as severe flank pain, which radiates from the back to the groin, or the presence of blood in the urine (hematuria). If kidney stones are suspected, a medical professional will often order a computed tomography (CT) scan. This advanced imaging technique is highly effective in identifying the precise presence, number, and exact location of any kidney stones, providing critical information for diagnosis and management. The CT scan can visualize even small stones that might be missed by other imaging modalities.

Once the presence of kidney stones is confirmed, it becomes imperative for your healthcare provider to determine their chemical composition. This step is vital because the type of stone dictates the most appropriate treatment strategy. The most reliable method for composition analysis is to chemically examine stones that have already been passed in the urine. Additionally, tests measuring uric acid levels in the urine over a 24-hour period and evaluating urine acidity (pH) can offer further insights, guiding medical professionals in developing targeted preventive measures and therapies to mitigate future stone formation.

Pseudogout

Similar to gout, the definitive diagnosis of calcium pyrophosphate deposition (CPPD) disease ultimately hinges on the identification of CPPD crystals within the affected joint fluid. This crucial diagnostic step confirms the presence of these specific crystals, distinguishing pseudogout from other forms of arthritis that may present with similar inflammatory symptoms. A thorough arthrocentesis procedure, performed by a trained healthcare professional, is essential to obtain the necessary synovial fluid for accurate microscopic analysis, providing the clearest insight into the cause of the patient's joint inflammation.

Under polarized light microscopy, the distinguishing feature of CPPD crystals, which sets them apart from the uric acid crystals of gout, is their optical property: they appear blue when aligned parallel to the compensator, a characteristic known as "positive birefringence." This allows for a clear differentiation. Beyond crystal analysis, advanced imaging techniques like Single-Photon Emission Computed Tomography (SPECT CT) and musculoskeletal ultrasound are increasingly utilized to identify areas of crystal deposition in joints and surrounding tissues, providing additional diagnostic support and insights into the extent of the disease.

Even if crystal analysis is not immediately available or inconclusive, the diagnosis of CPPD disease may be strongly suspected based on a combination of the patient's clinical history and specific findings on X-rays. Your healthcare provider might suspect CPPD if you present with acute arthritis primarily affecting larger joints, particularly the knees. This suspicion is further heightened in older patients, especially those over 65, where CPPD disease is more prevalent. Given its varied presentation, CPPD disease often mimics other common arthritic conditions, including osteoarthritis or rheumatoid arthritis, making a detailed clinical evaluation paramount.

Treatment

Gout

The primary objective in managing an acute gout attack is to swiftly alleviate pain and reduce the intense inflammation. This critical goal is typically achieved through the judicious use of specific anti-inflammatory medications. The cornerstone of treatment includes nonsteroidal anti-inflammatory agents (NSAIDs), which effectively reduce swelling and pain; steroid medications, potent anti-inflammatories that can be administered orally or by injection; and colchicine, a traditional medication that targets inflammation caused by uric acid crystals. Timely intervention is crucial for providing rapid relief and preventing the progression of the flare.

All three classes of medications—NSAIDs, steroids, and colchicine—are available in oral formulations, offering convenience for patients. The selection of the most appropriate drug is a carefully considered decision, tailored to each patient's individual circumstances. Factors influencing this choice include the patient's tolerance for specific drugs, the presence of any coexisting medical conditions that might preclude the use of certain medications (e.g., kidney disease for NSAIDs, diabetes for steroids), and the severity of the flare. For optimal effectiveness, treatment should ideally be initiated within 24 hours of the onset of symptoms, helping to quickly resolve the acute episode.

In cases of chronic gout, the long-term treatment strategy shifts focus toward lowering uric acid levels in the blood, a measure designed to prevent recurrent acute attacks and minimize crystal deposition. There are two primary pharmacological approaches to achieve this. One involves administering drugs that work by decreasing the body's production of uric acid, such as allopurinol and febuxostat. The other strategy utilizes medications like probenecid, which increase the excretion of uric acid through the urine, effectively reducing its accumulation in the bloodstream and tissues.

For patients whose gout remains refractory to conventional uric acid-lowering therapies, a specialized medication called pegloticase offers an alternative. This drug functions by actively breaking down uric acid, effectively metabolizing it into a more soluble compound that can be excreted. The decision to initiate long-term uric acid-lowering therapy is highly individualized, considering various factors such as the frequency of a person's acute attacks, the persistently high levels of uric acid in their blood, and the presence of tophi, which indicate significant crystal burden. This personalized approach ensures the most effective long-term management.5

It is crucial to understand that while uric acid-lowering therapy is essential for preventing future gout attacks, it can paradoxically precipitate or worsen an acute flare when first introduced. For this reason, these medications are strictly avoided during an active acute attack. To mitigate this risk and ensure patient comfort, anti-inflammatory medications are often prescribed concurrently with the initial phase of uric acid-lowering therapy. This prophylactic anti-inflammatory cover helps to suppress any potential flare-ups that might occur as the body adjusts to changes in uric acid levels.

Once initiated, therapy with uric acid-lowering medications is generally a lifelong commitment, making consistent adherence critically important for sustained control of gout. Regular monitoring of uric acid levels and adherence to prescribed dosages are key to preventing recurrences and long-term complications. Furthermore, given that diet and lifestyle choices significantly influence uric acid levels, your healthcare provider will often recommend complementary strategies. These include adopting a healthy, balanced diet, limiting the consumption of purine-rich foods, and reducing alcohol intake, all of which contribute to better management of the condition.

Pseudogout

The primary aim of pseudogout treatment is predominantly to alleviate symptoms and manage the inflammatory responses caused by crystal deposition. Similar to the therapeutic approach for gout, anti-inflammatory medications form the cornerstone of acute pseudogout management. Nonsteroidal anti-inflammatory agents (NSAIDs), steroid medications (which can be given orally or by injection), and colchicine are commonly utilized to reduce the pain, swelling, and redness associated with acute episodes. The choice of medication depends on the severity of the attack, patient comorbidities, and individual tolerance.

When an acute pseudogout flare is confined to a single joint, healthcare providers often consider a localized treatment strategy involving arthrocentesis. This procedure entails draining the excess fluid accumulated within the joint, which can immediately relieve pressure and reduce pain. Following fluid removal, steroids may be injected directly into the joint space. This intra-articular steroid injection delivers potent anti-inflammatory medication precisely to the site of inflammation, often leading to rapid and significant relief of joint pain and swelling. For patients experiencing frequent CPPD attacks, a low-dose, daily regimen of colchicine may be prescribed as a prophylactic measure to effectively reduce the number and severity of recurrent episodes.

A Word From Verywell

Crystal-induced arthropathies, such as gout and calcium pyrophosphate deposition (CPPD) disease, can inflict considerable pain and significantly impair an individual's quality of life. The acute inflammatory episodes are often excruciating, and chronic disease can lead to irreversible joint damage and systemic complications. Fortunately, medical science has made significant strides in understanding and managing these conditions. A diverse array of treatment options is now available, enabling healthcare providers to effectively control the disease burden and often prevent long-term sequelae through targeted medications and interventions.

Effective treatment for crystal-induced arthropathies is inherently individualized, tailored to the unique clinical profile of each patient. The specific therapeutic strategy will depend on various factors, including the severity and frequency of your symptoms, the specific type of crystals involved, and the presence of any coexisting medical conditions that might influence treatment choices. We strongly encourage you to engage in an open and detailed discussion with your healthcare provider. Together, you can collaboratively develop a comprehensive treatment plan that addresses your specific needs and optimizes your health outcomes.

5 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

  1. Elfishawi MM, Zleik N, Kvrgic Z, et al. The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol. 2018;45(4):574-579. doi:10.3899/jrheum.170806
  2. Harvard Health Publishing. Pseudogout (CPPD).
  3. Major TJ, Topless RK, Dalbeth N, Merriman TR. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ. 2018 Oct 10;363:k3951. doi:10.1136/bmj.k3951
  4. American Academy of Family Physicians. Pseudogout.
  5. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711-720. doi:10.1001/jama.2011.1169

Additional Reading